Prospective observational pilot study of quantitative light dosimetry in erythropoietic protoporphyria.
Prospective observational pilot study of quantitative light dosimetry in erythropoietic protoporphyria.
复制标题
红细胞生成性原卟啉症定量光剂量测定的前瞻性观察性试点研究。
DOI：
10.1016/j.jaad.2022.11.036
复制
发表时间：
2023
影响因子：
13.8
通讯作者：
Christiani,David
中科院分区：
文献类型：
--
作者：
Dickey,AmyK;Rebeiz,Lina;Raef,Haya;Leaf,RebeccaK;Elmariah,Sarina;Naik,Hetanshi;Anderson,Karl;Conley,Jared;Iyasere,Christiana;Zhao,Sophia;Birkenfeld,JudithS;Arroyo-Gallego,Teresa;Wheeden,Kristen;Ducamp,Sarah;Christiani,David
资金来源/鸣谢：这项工作是通过47 MGH医学创新计划火花创新奖的资助和MGH 48医疗保健转型实验室和哈佛催化剂的支持完成的。哈佛催化剂由49哈佛临床和转化科学中心（国家中心推进50转化科学，美国国立卫生研究院奖UL 1 TR 002541）和哈佛51大学及其附属学术医疗保健中心支持。Dickey博士获得了52 NIH NIAMS K23资助1 K23 AR 079586 -01。作者感谢麻省理工学院linQ IDEA 2项目53在开发本项目中提供的支持和指导。他们还要感谢所有参与研究的患者54以及坎迪斯·科尔伯特的有益见解和反馈。55 56利益冲突：Dickey博士是Alnylam Pharma和Recordati Pharma的顾问，57已获得Disc Medicine的资助，用于单独的研究。安德森博士58报告说，他从Alnylam制药公司收到讲课费、咨询费、咨询委员会费和大学赠款59，从Recordati制药公司收到咨询费、咨询委员会费和赠款60，从三菱田边制药公司收到咨询费和赠款。Karp博士已收到三菱田边制药、Alnylam制药和Recordati制药的61笔咨询费。62弗莱明博士是椎间盘医学科学咨询委员会的成员。Rebeiz女士从Alnylam Pharma获得了63笔咨询和咨询委员会费用。所有其他共同作者报告64例无利益冲突。65
Funding Sources/Acknowledgements: This work was completed through funding from an 47 MGH Medicine Innovation Program Spark Innovation Award and support from the MGH 48 Healthcare Transformation Laboratory and Harvard Catalyst. Harvard Catalyst is supported by 49 the Harvard Clinical and Translational Science Center (National Center for Advancing 50 Translational Sciences, National Institutes of Health award UL1TR002541) and Harvard 51 University and its affiliated academic health care centers. Dr. Dickey received funding from a 52 NIH NIAMS K23 grant 1K23AR079586-01. The authors thank the MIT linQ IDEA2 program 53 for support and guidance in developing this project. They would also like to thank all the patients 54 who participated in the study as well as Candace Colbert for her helpful insights and feedback. 55 56Conflicts of Interest: Dr. Dickey is a consultant for Alnylam Pharma and Recordati Pharma and 57 has received grant support from Disc Medicine for a separate research study. Dr. Anderson 58 reports receiving lecture fees, consulting fees, advisory board fees, and grants to the university 59 from Alnylam Pharma, consulting fees, advisory board fees, and grants from Recordati Pharma, 60 and consulting fees and grants from Mitsubishi Tanabe Pharma. Dr. Karp has received 61 consulting fees from Mitsubishi Tanabe Pharma, Alnylam Pharma, and Recordati Pharma. Dr. 62 Fleming is a member of the Scientific Advisory Board of Disc Medicine. Ms. Rebeiz has 63 received consulting and advisory board fees from Alnylam Pharma. All other co-authors report 64 no conflicts of interest. 65